Preliminary Results Regarding the Feasibility and Outcomes of MR-Linac Adaptive Stereotactic Body Radiotherapy Combined with Systemic Treatment Among Patients with Pelvic–Abdominal Recurrent or Metastatic Gynecological Malignancies: A Single-Institution Experience
Open Access
Abstract
Objective: Inadequate radiation delivery to recurrent pelvic and abdominal tumors is frequently attributable to the dose limitations of surrounding normal structures, particularly the intestines. Radiotherapy guided by magnetic resonance imaging (MRI) significantly enhances the accuracy of soft-tissue delineation. The purposes of this study were to demonstrate the feasibility and effectiveness of MR-Linac Adaptive stereotactic body radiotherapy in patients with pelvic–abdominal recurrent or metastatic gynecological malignancies with or without systemic therapies. Methods: Patients with pelvic–abdominal recurrent or metastatic gynecological malignancies are eligible for MR-Linac Adaptive stereotactic body radiotherapy. Systemic therapies, including chemotherapy, immunotherapy, and targeted therapy, are considered acceptable treatment options. The safety, tolerability, and efficacy of MR-Linac Adaptive stereotactic body radiotherapy were assessed. Results: Between October 2019 and May 2025, 15 patients were subjected to MR-Linac Adaptive stereotactic body radiotherapy. With a median follow-up period of 4.67 months (range, 0.73–20.10 months), the 6-month overall survival (OS), progression-free survival (PFS), and local control (LC) rates were 93.3%, 66.0%, and 92.3%, respectively. The 12-month OS, PFS, and LC rates were 83.8%, 37.7%, and 70.5%, respectively. The best objective response rate (ORR = CR + PR) for the irradiated lesions was 73.3% (11/15 patients). MR-Linac Adaptive stereotactic body radiotherapy led to objective responses in 73.3% (11/15) of the patients. As of the data cutoff (28 May 2025), one patient experienced dose-limiting toxicity (an enteric fistula). Another patient developed grade 4 thrombocytopenia during treatment; it was considered chemotherapy-induced. Conclusions: These findings suggest that MR-Linac Adaptive stereotactic body radiotherapy is relatively effective and safe and can be an important treatment option for patients with pelvic–abdominal recurrent or metastatic gynecological malignancies. MR-Linac Adaptive stereotactic body radiotherapy exhibited acceptable tolerability, promising efficacy, and a favorable local control rate with regard to heavily pretreated advanced solid tumors.Keywords
This publication has 23 references indexed in Scilit:
- Adverse Events After Metastases-Directed Stereotactic Radiotherapy and Biological Cancer TherapyJAMA Network Open, 2026
- Online Adaptive Magnetic Resonance-guided Radiation Therapy for Gynaecological Cancers: Preliminary Results of Feasibility and OutcomeClinical Oncology, 2023
- Radiotherapy remodels the tumor microenvironment for enhancing immunotherapeutic sensitivityCell Death & Disease, 2023
- Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: systematic review and consensus recommendations by the EORTC–ESTRO OligoCare consortiumThe Lancet Oncology, 2023
- European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus on re-irradiation: definition, reporting, and clinical decision makingThe Lancet Oncology, 2022
- Radiation Therapy Promotes Hepatocellular Carcinoma Immune Cloaking via PD-L1 Upregulation Induced by cGAS-STING ActivationInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2022
- Incorporating Magnetic Resonance Imaging (MRI) Based Radiation Therapy Response Prediction into Clinical Practice for Locally Advanced Cervical Cancer PatientsSeminars in Radiation Oncology, 2020
- Immunological impact of cell death signaling driven by radiation on the tumor microenvironmentNature Immunology, 2019
- Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)The Lancet, 2017
- Online MRI guidance for healthy tissue sparing in patients with cervical cancer: An IMRT planning studyRadiotherapy and Oncology, 2008